Avidity Biosciences, Inc. - RNA STOCK NEWS

Avidity Biosciences, Inc. (Nasdaq: RNA) announced the pricing of an underwritten public offering of 12,000,000 shares at $17.25 per share, aiming for gross proceeds of approximately $207 million. The offering, closing around December 20, 2022, is intended to fund research and development of its RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™). The company also granted underwriters a 30-day option for an additional 1,800,000 shares. This offering is registered with the SEC under an effective shelf registration statement.

Avidity Biosciences (Nasdaq: RNA) announced a proposed public offering of $150 million in common stock, with a potential additional 15% from underwriters. The proceeds aim to support research and development, enhance its AOC platform, and cover general corporate expenses. This offering will be made under a shelf registration statement filed with the SEC, with no assurance on completion timing or final terms. The underwriters include Cowen, Evercore ISI, and Wells Fargo Securities.

Avidity Biosciences (RNA) announced promising Phase 1/2 MARINA trial results for AOC 1001, the first successful targeted delivery of siRNA to muscle in humans. Key findings include a 45% mean reduction in DMPK across all participants, with splicing improvement of 31% in muscle-specific genes. Early clinical activity was noted, with improvements in myotonia observed in some adults with DM1. The company is actively working to lift a partial clinical hold on new participant enrollment. AOC 1001 aims to address the root cause of myotonic dystrophy type 1 (DM1), a life-threatening condition without approved therapies.

Avidity Biosciences (RNA) reported Q3 2022 results, highlighting advances in three rare disease programs: DM1, FSHD, and DMD. The MARINA trial for AOC 1001 is set for a preliminary assessment this quarter, despite a partial clinical hold due to a serious adverse event. The company has a cash runway of approximately $425 million through 2024, supporting its AOC platform expansion. Q3 collaboration revenue rose to $2.5 million, while R&D expenses increased to $37.3 million, reflecting ongoing clinical developments.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company specializing in RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced upcoming conference participation. The company will present at the 31st Annual Credit Suisse Healthcare Conference on November 8 at 11:00 a.m. PT and the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 7:30 a.m. PT. Live webcasts and event details will be available on their website. Avidity is advancing three programs in clinical development targeting various muscular dystrophies.

Avidity Biosciences has initiated the Phase 1/2 EXPLORE44 clinical trial for AOC 1044, targeting Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping. AOC 1044 is the first antibody oligonucleotide conjugate engineered to deliver phosphorodiamidate morpholino oligomers to treat DMD. This marks a significant step forward as there are currently no approved therapies for DMD44. The trial aims to assess the safety and efficacy of AOC 1044 in healthy volunteers and DMD patients, with enrollment expected for 64 participants.

Avidity Biosciences, Inc. (Nasdaq: RNA) announced it will present five poster presentations at the 27th International Hybrid Annual Congress of the World Muscle Society from October 11-15, 2022, in Halifax, Nova Scotia. Key presentations include the MARINA™ study for myotonic dystrophy type 1 and data on facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD). Notable presentations are scheduled for October 14, including a Phase 1/2 trial of AOC 1001 in adults with myotonic dystrophy type 1.

Avidity announced the initiation of the Phase 1/2 FORTITUDE clinical trial for AOC 1020, targeting facioscapulohumeral muscular dystrophy (FSHD), affecting 16,000-38,000 individuals in the U.S. AOC 1020 aims to address the underlying cause of FSHD by targeting the DUX4 gene. This is Avidity's second siRNA AOC to enter clinical development, adding to their portfolio of three rare disease programs, including myotonic dystrophy type 1 and Duchenne muscular dystrophy. The trial will evaluate safety and tolerability, with a preliminary safety assessment expected in Q4 2022.

Avidity Biosciences (Nasdaq: RNA) announced a partial clinical hold by the FDA on new participant enrollment in the Phase 1/2 MARINA™ trial of AOC 1001 for myotonic dystrophy type 1 (DM1) due to a serious adverse event in a participant. Around 40 participants continue in the ongoing MARINA and MARINA-OLE™ trials, but no new enrollments are permitted until the issue is resolved. Avidity received IND clearance for AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD) and AOC 1044 for Duchenne muscular dystrophy (DMD), advancing these programs into clinical trials.